Gaucher Disease
📧 Sign up to get email alerts when something new happens for Gaucher Disease.
Sign up freeTop drugs studied for this disease
-
EMA guidance · 2017-07-03EMA and FDA encourage use of innovative approaches in the development of medicines for Gaucher disease
EMA and FDA encourage the use of innovative development approaches to speed up and improve medicines for Gaucher disease.
-
EMA guidance · 2014-05-14European Medicines Agency and US Food and Drug Administration release joint proposal to facilitate clinical investigation of new medicines for Gaucher disease in children
The EMA and FDA released a joint proposal to facilitate clinical investigations of new medicines for Gaucher disease in children.
-
EMA guidance · 2009-10-22Updated temporary treatment recommendations for Cerezyme
EMA updated temporary treatment recommendations for Cerezyme (imiglucerase) related to its use, dosing, and monitoring guidelines.
-
EMA guidance · 2009-06-25Supply shortages of Cerezyme and Fabrazyme - priority access for patients most in need of treatment recommended
EMA recommends priority access to Cerezyme and Fabrazyme during supply shortages to ensure treatment for patients most in need.